Information  X 
Enter a valid email address

SkinBioTherapeutics (SBTX)

  Print   

Monday 19 April, 2021

SkinBioTherapeutics

Holding(s) in Company

RNS Number : 9312V
SkinBioTherapeutics PLC
19 April 2021
 

TR-1: S tandard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i


1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii :

SkinBioTherapeutics plc

 

Company No: 09632164 (England)

 

1b. Please indicate if the issuer is a non-UK issuer   (please mark with an "X" if appropriate)

Non-UK issuer


2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

x

An acquisition or disposal of financial instruments


An event changing the breakdown of voting rights


Other (please specify)iii:


3. Details of person subject to the notification obligation iv

Name

Seneca Partners Limited

City and country of registered office (if applicable)

Haydock, Greater Manchester UK

4. Full name of shareholder(s) (if different from 3.) v

Name

WCS Nominees Limited, Platform Securities Nominees Limited.

City and country of registered office (if applicable)

London UK

5. Date on which the threshold was crossed or reached vi :

16/04/2021

6. Date on which issuer notified (DD/MM/YYYY):

19/04/2021

7. Total positions of person(s) subject to the notification obligation


% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments
(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuer vii

Resulting situation on the date on which threshold was crossed or reached

9.9


9.9

156,780,236

Position of previous notification (if

applicable)

10.4


10.4


 

 

 

Place of completion

Haydock, Greater Manchester UK

Date of completion

19 April 2021

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLILMITMTMBBPB

a d v e r t i s e m e n t